JPM decision memo, 18 Nov 2026
Bottom line
- Long-term investing: HOLD if you already own it. Do not start a new position at $327.06. JPMorgan is a high-quality bank (quality grade A), but the price already reflects that. The fundamental analyst's base value is about $315, below today's price. Its suggested accumulation zone is $270–295, which is roughly 10–17% below the current price.
- Swing trading: NO TRADE. the risk review rejected the oversold-bounce plan. Its reward-to-risk was 0.35 to the first target against a required 2.0. Wait for a better entry, described below.
- Day trading: NO TRADE. Both intraday plans were rejected, with reward-to-risk of 0.82 and 0.38 against a required 1.5. JPM is not "in play" today. The pattern-day-trader rule also limits a $10k margin account.
- Options: NO TRADE. The smallest sensible defined-risk spread can lose $270. Your per-options cap is $100.
- Biggest single risk: the market regime. SPY sits only +0.01% above its 200-day average. There have been 8 distribution days in 25 sessions, and VIX is 25.48 in backwardation. A break of SPY's 200-day, or of JPM's own 200-day at $322.83, would likely make a bad situation worse.
Long-term investment view
The business is excellent, but the price is not a bargain. ROE (return on equity, meaning profit per dollar of shareholder capital) is 15.7%, against a cost of equity of about 10.1%. So JPM creates value. Revenue has compounded at 12.5% a year, and the share count fell 6.35% through buybacks. The payout ratio is a modest 26% (/).
Why "hold" rather than "buy": banks are valued on price-to-book (P/B, the price relative to the accounting value of equity), not on a DCF. The negative FCF of −$147.8B reflects balance-sheet flows and is meaningless for a bank. Using ROE of 15.7% and growth of 4–5%, the justified P/B comes out at about 1.9–2.1x. The stock trades at 2.47x, so the market is already paying a premium.
Illustrative scenario math. The fundamental analyst's values are bear $250, base $315 and bull $375. With assumed weights of 25/50/25, the expected value is about $314, roughly 4% below today's price. These weights are my illustration, not analyst output. The result shows there is no margin of safety. Analysts are more optimistic, with a mean target of $373.48 (+14.2%). Their targets span from Citi's Neutral at $350 to Barclays' Overweight at $425.
There is no variant perception here. teaches that being right about a great company is not enough; you must differ from the market and explain why it is wrong. Our view (high-quality, fairly priced) is essentially the consensus view. So the edge is a patience edge: wait for the price to come to you.
Forensics (accounting checks). No red flags appear on the available signals, with a CLEAN verdict at modest confidence. The standard manipulation scores (Beneish, Altman, Piotroski) do not apply to banks. Two items still need reading: - An 8-K Item 5.02 officer change filed 17 Nov. Who left is unknown. - A batch of 424B2 filings on 18 Nov. These are probably structured notes, but that is unverified.
Thesis breakers (written in advance): - Charge-offs and provisions rising while reserve coverage falls. - ROE sliding toward the ~10% cost of equity. - CET1 capital nearing the regulatory minimum, or a cut to capital returns. - Revenue turning negative as net interest income falls.
The biggest data gap: NIM, CET1, ROTCE, NCO ratio and reserve coverage are all unknown. Treat every long-term conclusion above as provisional until you have them.
Swing trading view
Verdict: rejected by the risk review. Stay flat.
What the trading analyst proposed. A speculative RSI(2) bounce, where RSI(2) is a very short-term overbought/oversold gauge. The inputs were RSI(2) at 5.6 (deeply oversold) and the close of $327.06 just above the rising 200-day SMA of $322.83.
Why it was rejected: - The stop needed to sit below the 200-day. - Overhead resistance sits close, at $334.35 and $339.96. - That pairing gives only 0.35R to the first target and about 0.9R to the final target. A swing trade needs 2R or more.
The broader picture confirms caution: - Trend Template: 4 of 8 checks pass. - ADX 16.2, meaning no real trend. - Weinstein stage: 1/3 (basing or topping). - MACD has made a bearish cross. - CMF is −0.187, indicating net distribution. - JPM has lagged its sector by 6.44 points over 3 months.
What a valid swing setup would look like. These are not current plans. They describe conditions that could be re-submitted to the risk review: 1. Pullback that holds. Price dips to $324–325, holds above the 200-day, and prints a reversal candle. That allows a tighter stop and a better reward-to-risk. 2. Strength confirmation. A reclaim of $334–338 (the 10/21-day EMAs and Tenkan line) on rising volume. A clean trend trade would really need price back above the 50-day SMA at $338.38.
Either version still needs 2R or more and reduced size, because the macro analyst's guidance is "reduced."
Bearish watch item. A close below $325.61 or $324.25 would trigger Donchian breakdown signals. A close below $322.83 or $320 would suggest Stage 4 (a downtrend). Shorts are allowed in your profile, but no short plan has been submitted or approved.
Day trading view (today / next session)
Verdict: no trade. Both plans were rejected.
Conditions at 12:28 ET: - Price $327.06, just below VWAP of $327.62. VWAP is the volume-weighted average price, the intraday "fair" line. - 6 VWAP crosses so far, which signals chop. - RVOL (volume relative to normal) of 1.29, below the 1.5 "in play" threshold. - 59% of the average daily range already used.
The two plans: - The VWAP-reclaim long offered 0.82R. - The VWAP-rejection short offered 0.38R, because it was shorting straight into support at $325.61.
Both fall short of the 1.5R minimum (risk rules).
Account constraint. Under $25k in a US margin account, frequent day trades can trigger the pattern-day-trader (PDT) restriction. For this account, a well-built swing usually beats a marginal day trade.
Next session. Treat the prior-day close (PDC) of $329.96, today's low of $325.61 and the 200-day at $322.83 as the reference levels. Only act if JPM becomes "in play" on a real catalyst and offers 1.5R or more.
Options view
No recommendation.
Implied volatility is cheap-to-fair: - ATM IV (the market's expected volatility) is 26.3%. - 20-day realized volatility is 29.4%, giving an IV/HV ratio of 0.89. - The 30-day expected move is ±5.96%, a range of $307.56–346.56. - Earnings are 57 days away, so there is no "IV crush" problem.
In principle, that favors buying defined-risk debit spreads over selling premium.
But the size does not fit. The 325/330 December bull call spread has a $270 maximum loss, against a $50 per-trade budget and a $100 options cap. Every other structure is worse: - Credit spreads and the iron condor risk about $380–390. - A cash-secured put needs $31,500. - Weekly options are illiquid, with spreads around 10.5% of mid.
The lesson: a small account sometimes simply cannot express a view in options on a $327 stock.
Where the analysts disagree
| Topic | One side | Other side | Who is stronger, by horizon |
|---|---|---|---|
| Value | Analysts: Buy, mean target $373.48 | Fundamental: base $315, justified P/B ~2.1x vs 2.47x | Investing horizon goes to fundamentals, but with caveats. ROTCE is unknown and likely above ROE, which would justify a higher multiple. The fundamental analyst's g=4% is its own assumption. |
| Short-term direction | Technical: RSI(2) 5.6 oversold, price above a rising 200-day, bounce possible | Flow and macro: CMF −0.187, falling OBV, 8 SPY distribution days, VIX backwardation | Swing horizon leans to the regime and flow side. Oversold readings in a stressed market can stay oversold (the "falling knife" risk). |
| Macro for banks | A positive curve (10y–3m +0.77pp) supports net interest margin. XLF leads SPY by 3.97 points. | CPI 4.08%, a 10-year yield above 5%, and HY spreads widening slightly to 3.43pp | Net NEUTRAL. The curve helps earnings while high yields and credit risk cap multiples. |
| Positioning | Institutions net adding (top 10: 6 adding). Short interest is tiny at 0.9%. | Only insider sales (3 sales, $3.59M). Bank of America cut its stake 29.5%. | Weak signals both ways. 13F data is stale by about 45 days. |
| Trading analyst vs risk review | Trading analyst offered conditional plans | risk review rejected all three on reward-to-risk | risk review is final. |
What to watch next (catalysts, levels, data)
Events and filings - 8-K Item 5.02 (filed 17 Nov): read it now. A surprise CFO or chief risk officer exit would be a warning sign. - 424B2 batch (18 Nov): confirm these are notes, not common-stock issuance. - Q4 earnings on 14 Jan 2027: consensus is EPS $5.86 and revenue $51.07B. The average earnings move is 2.12%, but gaps of about 4% have happened. Focus on charge-offs, reserves, NIM and CET1.
JPM price levels
| Level | Meaning |
|---|---|
| $324.36 / $322.83 | Support and the 200-day. A daily close below $322.83 or $320 is bearish (Stage 4 risk). |
| $334–338 | Reclaim zone. Reclaiming it on volume is the first sign of repair. |
| $338.38 | The 50-day SMA. |
| $359.8 | The breakout pivot, far away. |
| $270–295 | Long-term accumulation zone, if credit metrics are stable. |
Macro triggers (from the macro analyst) - SPY closing below its 200-day. - VIX staying above VIX3M, or rising above 30. - HY spread moving toward 4.5pp. - The 10y–3m curve narrowing toward zero. - CPI above 4.1%.
What would turn the view bullish: SPY reclaiming its 50-day with VIX back in contango, plus CMF turning positive or JPM's RS line making new highs.